The pH/enzyme cascade-responsive CRNPs utilize an ultra-pH-sensitive nanoplatform with CatB-cleavable linkers to achieve tumor-selective PROTAC release, transitioning from stable 33 nm nanoparticles under physiological conditions to activated degraders in the acidic TME (Figure 4B) [44]. This evidence concerns the gene TYRP1 and neoplasm.